Healthcare / Medical DevicesKOSDAQ
$2080.00
+35.00 (+1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-14.5B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-151.4%
↓Gross Margin
25.5%
↓Debt/Equity
1.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+67.3%
FCF CAGR
—
FCF margin
-36.6%
FCF / Net income
0.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.97B · net income $-34.94B · FCF $-9.87B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.97B | $26.97B | $4.87B | $5.20B | $5.75B |
| Net Income | $-34.94B | $-34.94B | $-7.68B | $-13.42B | $-10.34B |
| EBITDA | $-23.83B | $-23.83B | $-2.20B | $-11.26B | $-8.39B |
| EPS | -1093.00 | -1093.00 | -196.63 | -536.51 | -420.39 |
| Gross Margin | 25.5% | 25.5% | 43.7% | 20.7% | 26.8% |
| Operating Margin | -31.8% | -31.8% | -272.9% | -243.4% | -221.1% |
| Net Margin | -129.6% | -129.6% | -157.6% | -258.1% | -179.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.28 | 1.28 | 1.83 | 1.48 | 0.54 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.87B | $-9.87B | $-14.54B | $-19.69B | $-16.92B |
| Returns | |||||
| ROE | -151.4% | -151.4% | -31.7% | -43.0% | -26.3% |
| Valuation | |||||
| P/B | 2.75 | 2.75 | 4.89 | 4.84 | 5.33 |
| Growth & Yield | |||||
| Revenue Growth | 453.3% | 453.3% | -6.3% | -9.7% | — |
| EPS Growth | -455.9% | -455.9% | 63.4% | -27.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-196.63 → -1093.00
Residual
-39.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.